today announces the availability of a new white paper demonstrating the advanced capabilities of the novel RapidFACT approach: an integrated formulation development, manufacture and clinical testing service. RapidFACT can be used to optimise drug products with significantly shorter timelines and reduced associated expenditure compared to traditional approaches. The new white paper, entitled "RapidFACT - a New Paradigm for the Effective Optimisation of Oral Dosage Forms", is available to download free-of-charge.
A conventional drug product optimisation process involves iterative rounds of screening multiple formulation prototypes in preclinical species to identify a limited number of "lead" systems to progress into human clinical PK studies. This process is time consuming and expensive, costing over £1m and taking over 18 months. Quotient's RapidFACT service can reduce this timeline by up to two thirds and significantly reduces associated costs.
RapidFACT exploits Quotient's Translational Pharmaceutics platform which integrates formulation development, GMP drug product manufacture and clinical testing facilities to allow products to be manufactured and investigated in a clinical study in timeframes as short as 24 hours. Candidate formulations can be rapidly screened, selected and validated on the basis of human clinical data. This significantly improves the precision by which an optimal drug product that matches the desired target product profile can be identified.
Mark Egerton, Chief Executive Officer of Quotient Clinical comments, "The increasingly competitive nature of the pharmaceutical industry inevitably means that any approach which saves time and money and increases the chances of development success, is welcomed by our clients. We have now completed RapidFACT programs for a number of our pharma and biotech clients and the results have been very pleasing. We have clearly demonstrated our ability to accelerate early development".
To find out more about RapidFACT or to obtain a copy of the new white paper please email or call Quotient Clinical on +44 (0)115 9749000 for further information.
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. T: +44 1477 539 539 F: +44 1477 539 540 E: quotient[.]scottpr.com.
About Quotient Clinical
Quotient Clinical is a strategic business unit of Quotient Bioresearch. It was formed in May 2009 following the acquisitions of two companies, Charles River Laboratories' Edinburgh clinical research facility in May 2009 (formerly Inveresk Clinical Research) and Pharmaceutical Profiles in December 2008. Quotient Clinical specialises in early clinical drug development, and offers a unique streamlined process to reduce the time from First-in-Man studies through to proof of concept, integrating flexible drug product manufacture into clinical trials. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.
About Quotient Bioresearch
Quotient is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units - Quotient Chemistry & Metabolism, Quotient Bioanalytical Sciences and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch (quotientbioresearch.com) is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.